The article discusses the research paper "Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)," by Ben Tran, L. Horvath, T. Dorff, et al., which was presented at the 2020 European Society for Medical Oncology Virtual Congress held on September 19-21. Also detailed are the safety and the antitumor activity of AMG 160.